G1 Therapeutics Provides Third Quarter 2022 Financial
- Achieved $23.6 million in Total Revenue in the Third Quarter of 2022 Including $8.3 million in Net Revenue from Sales of COSELA® (trilaciclib) - -...
Source: globenewswire.com
Stay updated with breaking news from Initial Safety Data. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
- Achieved $23.6 million in Total Revenue in the Third Quarter of 2022 Including $8.3 million in Net Revenue from Sales of COSELA® (trilaciclib) - -...